Aquestive Therapeutics Presented Positive Topline Phase 1 Results for AQST-109 Epinephrine Oral Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
February 28, 2022 20:33 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care...
Aquestive Therapeutics Reports Positive Topline Data from Part 1 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
February 25, 2022 07:00 ET
|
Aquestive Therapeutics, Inc.
First and only orally delivered epinephrine product candidate AQST-109 continues to show rapid absorption with a median time to peak concentration (Tmax) of 13.5 minutes AQST-109 was safe and well...
Aquestive Therapeutics Announces FDA Clearance of Investigational New Drug Application (IND) for AQST-109 Epinephrine Oral Film
February 24, 2022 21:26 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care...
Aquestive Therapeutics to Report Fourth Quarter and Year End 2021 Financial Results and Recent Business Highlights on March 8 and Host Conference Call on March 9 at 8:00 a.m. ET
February 22, 2022 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company improving and advancing medicines to solve patients’ problems with current...
Aquestive Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
January 07, 2022 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address...
Aquestive Therapeutics Receives Notification from FDA that It Will Not Be Ready to Take Action by December 23, 2021 for the Company’s NDA for Libervant™ (diazepam) Buccal Film
December 20, 2021 22:49 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address...
Aquestive Therapeutics Added to NASDAQ Biotechnology Index
December 17, 2021 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that...
Aquestive Therapeutics Receives Written Response to Pre-IND Submission for AQST-109 (epinephrine prodrug sublingual film) and Begins Recruitment for its Epinephrine Film Pharmacokinetic and Safety Trial (EPIPHAST)
December 13, 2021 08:00 ET
|
Aquestive Therapeutics, Inc.
FDA confirms 505(b)(2) pathway is acceptable for the development of AQST-109FDA indicates AQST-109 has the potential for Fast Track designationHealth Canada provides clearance to commence the adaptive...
Aquestive Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
November 17, 2021 08:00 ET
|
Aquestive Therapeutics, Inc.
WARREN, N.J., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address...
Aquestive Therapeutics Reports Third Quarter 2021 Financial Results, Provides Business Update and Improves Full Year Guidance
November 02, 2021 16:30 ET
|
Aquestive Therapeutics, Inc.
Libervant™ (diazepam) Buccal Film continues to progress through the FDA review process in advance of PDUFA goal date of December 23, 2021AQST-109 top line Phase 1 trial demonstrates clinical results...